Special Offer: Get 50% off your first 2 months when you do one of the following
Personalized offer codes will be given in each session
About This Webinar

ViewRay, Inc. (Nasdaq: VRAY) will host a virtual physician-led informational discussion for investors and analysts during the 2020 American Society of Radiation Oncology (ASTRO) Annual Meeting.

About ViewRay
ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures, and markets the MRIdian® radiation therapy system. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purpose built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.

Forward-Looking Statements
Forward-looking statements within the meaning of Section 27A of the Private Securities Litigation Reform Act. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, the rate of new orders, upgrades, and installations, ViewRay's anticipated future operating and financial performance, and ViewRay's conference calls to discuss its quarterly results. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to commercialize MRIdian Linac System, demand for ViewRay's products, the ability to convert backlog into revenue, the timing of delivery of ViewRay's products, the timing, length, and severity of the recent COVID-19 (coronavirus) pandemic, including its impacts across our businesses on demand, operations and our global supply chains, the results and other uncertainties associated with clinical trials, the ability to raise the additional funding needed to continue to pursue ViewRay's business and product development plans, the inherent uncertainties associated with developing new products or technologies, competition in the industry in which ViewRay operates, and overall market conditions. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to ViewRay's business in general, see ViewRay's current and future reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2019, and its Quarterly Reports on Form 10-Q, as updated periodically with the company's other filings with the SEC. These forward-looking statements are made as of the date of this press release, and ViewRay assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.

Contact:

Investor Relations:
Michaella Gallina
Chief of Staff, Head of Investor Relations and Communications
ViewRay, Inc.
1-844-MRIdian (674-3426)
Email: investors@viewray.com

Media Enquiries:
Karen Hackstaff
Vice President, Strategy and Brand
ViewRay, Inc.
1-844-MRIdian (674-3426)
Email: media@viewray.com

When: Tuesday, October 27, 2020 · 09:00:00 AM · Mountain Time (US & Canada)
Duration: 1 hour
Language: English
Who can attend? Anyone with the event link can attend
Dial-in available? (listen only): No
Featured Presenters
Webinar hosting presenter
Associate Professor of Radiation Oncology
Dr. Mak is an Associate Professor of Radiation Oncology at Harvard Medical School and Director of Clinical Innovation, Thoracic Radiation Oncology Disease Site Leader, and Director of Patient Safety/Quality in the Department of Radiation Oncology at DFBWCC. Dr. Mak led the implementation of MR-guided radiation therapy at DFBWCC and is a member of the Department’s MRIdian Adaptive Treatment Team.
Webinar hosting presenter
Director of MR-Guided Radiation Therapy and Proton Therapy, Miami Cancer Institute
Michael Chuong, M.D., is a board-certified radiation oncologist with Miami Cancer Institute, a part of Baptist Health South Florida. At Miami Cancer Institute he is the Medical Director of the Proton Therapy Center, the Physician Director of the MRI-Guided Radiation Therapy Program, and the Director of Radiation Oncology Clinical Research. As an internationally recognized expert in the use of radiation therapy for gastrointestinal cancers, he serves on several national committees including the NRG Oncology GI committee and is the Disease Site Chair for the Proton Collaborative Group. He is also the Principal Investigator of several clinical trials exploring novel combinations of advanced radiation technologies with systemic therapies such as immunotherapy.
Webinar hosting presenter
President and Chief Executive Officer
Scott Drake, President and Chief Executive Officer
Scott Drake is a proven leader in the medical device space. He is the President and CEO of ViewRay, an MRI-guided radiation therapy company with leading technology. Previously, Scott was President and CEO of Spectranetics, a publicly traded medical device company that was sold to Royal Philips for $2.2B. Prior to Spectranetics, he spent 17 years in leadership positions within numerous health care business units at Covidien, including President of Covidien’s Respiratory and Monitoring Solutions Global Business. Drake serves as Chairman of the Board for AtriCure (NASDAQ: ATRC) and as the Chairperson of the AdvaMed Radiation Therapy Sector. He previously served on the Board of Directors for The Zayo Group Holdings, Inc. (NASDAQ: ZAYO). In 2014 he was named an Ernst and Young Entrepreneur of the Year.
Hosted By
ViewRay webinar platform hosts ViewRay Physician-led Webinar for Investors and Analysts at 2020 ASTRO Annual Meeting
ViewRay's webinars